SHORT MINI-FUTURE - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 11:34:37 21/05/2024 pm IST | ||
| 18.09 EUR | +2.73% |
|
| Current month | -8.71% | ||
| 1 month | -18.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 18.09 | +2.73% |
| 20/24/20 | 17.61 | -0.90% |
| 17/24/17 | 17.77 | -0.06% |
| 16/24/16 | 17.78 | +3.67% |
| 15/24/15 | 17.15 | -6.03% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 11:34 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ8L90 |
| ISIN | DE000VQ8L907 |
| Date issued | 14/06/2021 |
| Strike | 421.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.96 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.77 € |
|---|---|
| Lowest since issue | 1.71 € |
| Spread | 0.03 € |
| Spread % | 0.17% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
231.6
USD
Average target price
285.9
USD
Spread / Average Target
+23.47%
- Stock Market
- Certificates
- Certificat